cas 1299607-55-8|| where to buy tert-Butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

Product Name:tert-Butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

IUPAC Name:tert-butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

Packing Unit	Available Stock	Price($)
CM151955-250mg	in stock	ǤƓ
CM151955-1g	in stock	ŗƥŉ
CM151955-5g	in stock	ůŹƥ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1299607-55-8 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1299607-55-8; Molecular Formula:C11H12BrN3O2; Melting Point:-; Smiles Code:O=C(N1N=CC2=CC(Br)=CN=C21)OC(C)(C)C; Density:

: Catalog Number:CM151955; Molecular Weight:298.14; Boiling Point:; MDL No:MFCD18803503; Storage:

: Pyrazolopyridines; Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

: Olverembatinib; Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.